An Overview of the Role of Prophylactic Surgery in the Management of Individuals with a Hereditary Cancer Predisposition

Surgical Clinics of North America

Volumn 88, Issue 4, 2008, Pages 739-758

  Oseni, Tawakalitu ^a   Jatoi, Ismail ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADENOMATOUS POLYP; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER SURGERY; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COLON CANCER; COLORECTAL CANCER; EARLY INTERVENTION; ESOPHAGOJEJUNOSTOMY; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL CANCER; GASTRECTOMY; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HETEROZYGOTE DETECTION; HUMAN; INFORMED CONSENT; MASTECTOMY; MEDICAL DECISION MAKING; NEUROFIBROMATOSIS; OVARY CANCER; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROCTOCOLECTOMY; REVIEW; RISK BENEFIT ANALYSIS; ROUX Y ANASTOMOSIS; SALPINGOOOPHORECTOMY; SIPPLE SYNDROME; STOMACH CANCER; THYROID CANCER; THYROIDECTOMY;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PROGNOSIS; SURGICAL PROCEDURES, OPERATIVE;

EID: 47849111839     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.04.010     Document Type: Review

References (123)

1. American Cancer Society. Cancer facts and figures 2006. Available at:. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf Accessed March 20, 2008
2. Knudson Jr. A.G. Retinoblastoma: a prototypic hereditary neoplasm. Semin Oncol 5 1 (1978) 57-60
3. Garber J.E., and Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 23 2 (2005) 276-292
4. Warthin A. Heredity with reference to carcinoma. Arch Intern Med 1 (1913) 546-555
5. Lynch H.T., et al. Hereditary factors in cancer. Study of two large Midwestern kindreds. Arch Intern Med 117 2 (1966) 206-212
6. Li F.P. Molecular epidemiology studies of cancer in families. Br J Cancer 68 2 (1993) 217-219
7. You Y.N., Lakhani V.T., and Wells Jr. S.A. The role of prophylactic surgery in cancer prevention. World J Surg 31 3 (2007) 450-464
8. Ries LAG, Melbert D, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2005/. Accessed March 20, 2008.
9. Ford D., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 3 (1998) 676-689
10. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 5645 (2003) 643-646
11. Risch H.A., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin cohort study in Ontario, Canada. J Natl Cancer Inst 98 23 (2006) 1694-1706
12. Galiatsatos P., and Foulkes W.D. Familial adenomatous polyposis. Am J Gastroenterol 101 2 (2006) 385-398
13. Annie Yu H.J., et al. Hereditary nonpolyposis colorectal cancer: preventive management. Cancer Treat Rev 29 6 (2003) 461-470
14. Lips C., et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331 13 (1994) 828-835
15. Lynch H.T., et al. Gastric cancer: new genetic developments. J Surg Oncol 90 3 (2005) 114-133 [discussion: 133]
16. Caldas C., et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 36 12 (1999) 873-880
17. Pharoah P.D., Guilford P., and Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121 6 (2001) 1348-1353
18. Narod S.A. Modifiers of risk of hereditary breast cancer. Oncogene 25 43 (2006) 5832-5836
19. Cullinane C.A., et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117 6 (2005) 988-991
20. Rebbeck T.R., et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 61 14 (2001) 5420-5424
21. Runnebaum I.B., et al. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 11 7 (2001) 635-638
22. Mathew C.G., et al. Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group. Lancet 337 8732 (1991) 7-11
23. Available at:. www.geneclinic.com Accessed March 20, 2008
24. Walsh T., et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295 12 (2006) 1379-1388
25. Rustgi A.K. The genetics of hereditary colon cancer. Genes Dev 21 20 (2007) 2525-2538
26. Barnetson R.A., et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354 26 (2006) 2751-2763
27. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21 12 (2003) 2397-2406
28. Aktan-Collan K., et al. Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer 93 4 (2001) 608-611
29. Jarvinen H.J. Genetic testing for polyposis: practical and ethical aspects. Gut 52 Suppl 2 (2003) ii19-ii22
30. Brown M.L., and Kessler L.G. The use of gene tests to detect hereditary predisposition to cancer: economic considerations. J Natl Cancer Inst 87 15 (1995) 1131-1136
31. Griffith G.L., Edwards R.T., and Gray J. Cancer genetics services: a systematic review of the economic evidence and issues. Br J Cancer 90 9 (2004) 1697-1703
32. Available at:. http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetest.shtml Accessed March 20, 2008
33. Johnson A. National conference of State Legislature. Genetics Brief Issue No VII June 2002. Available at:. http://www.ncsl.org/programs/health/genetics/Geneticshealthins.pdf Accessed March 20, 2008
34. Steel M., et al. Ethical, social and economic issues in familial breast cancer: a compilation of views from the E.C. Biomed II Demonstration Project. Dis Markers 15 1-3 (1999) 125-131
35. Matloff E.T., et al. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 18 12 (2000) 2484-2492
36. Peterson E.A., et al. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11 1 (2002) 79-87
37. Hall M.A., and Rich S.S. Patients' fear of genetic discrimination by health insurers: the impact of legal protections. Genet Med 2 4 (2000) 214-221
38. Rodriguez-Bigas M.A., et al. Health, life, and disability insurance and hereditary nonpolyposis colorectal cancer. Am J Hum Genet 62 3 (1998) 736-737
39. Dackiw A.P., Kuerer H.M., and Clark O.H. Current national health insurance policies for thyroid cancer prophylactic surgery in the United States. World J Surg 26 8 (2002) 903-906
40. Kuerer H.M., et al. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol 7 5 (2000) 325-332
41. Hall M.A. Legal rules and industry norms: the impact of laws restricting health insurers' use of genetic information. Jurimetrics 40 1 (1999) 93-122
42. Ramsoekh D., et al. The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP, and MAP. Clin Genet 72 6 (2007) 562-567
43. Pharoah P.D., et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31 1 (2002) 33-36
44. Hall J.M., et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science 250 4988 (1990) 1684-1689
45. Miki Y., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 5182 (1994) 66-71
46. Wooster R., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 5181 (1994) 2088-2090
47. Wooster R., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 6559 (1995) 789-792
48. Whittemore A.S., Gong G., and Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 60 3 (1997) 496-504
49. Meijer W.J., and van Lindert A.C. Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 47 1 (1992) 59-65
50. Parazzini F., et al. Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol 90 3 (1997) 453-456
51. Schairer C., et al. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 70 2 (1997) 150-154
52. Struewing J.P., et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 17 (1995) 33-35
53. Rebbeck T.R., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 17 (1999) 1475-1479
54. Rebbeck T.R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38 Suppl 6 (2002) S15-S17
55. Kauff N.D., et al. Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. J Clin Oncol 26 8 (2008) 1331-1337
56. Armstrong K., et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22 6 (2004) 1045-1054
57. Hartmann L.C., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 21 (2001) 1633-1637
58. Meijers-Heijboer H., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345 3 (2001) 159-164
59. Rebbeck T.R., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22 6 (2004) 1055-1062
60. Heemskerk-Gerritsen B.A., et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 14 12 (2007) 3335-3344
61. Pierce L.J., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24 16 (2006) 2437-2443
62. Chappuis P.O., et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18 24 (2000) 4045-4052
63. Haffty B.G., et al. Outcome of conservatively managed early onset breast cancer by BRCA1/2 status. Lancet 359 9316 (2002) 1471-1477
64. Metcalfe K., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22 12 (2004) 2328-2335
65. van Sprundel T.C., et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93 3 (2005) 287-292
66. Metcalfe K.A., et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26 7 (2008) 1093-1097
67. Horiguchi J., et al. Recurrence of breast cancer following local excision alone for ductal carcinoma in situ. Breast Cancer 8 1 (2001) 52-57
68. Peltomaki P., et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 260 5109 (1993) 810-812
69. Bodmer W.F., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328 6131 (1987) 614-616
70. Kinzler K.W., et al. Identification of an amplified, highly expressed gene in a human glioma. Science 236 4797 (1987) 70-73
71. Groden J., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66 3 (1991) 589-600
72. Spirio L., et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75 5 (1993) 951-957
73. Campbell W.J., Spence R.A., and Parks T.G. Familial adenomatous polyposis. Br J Surg 81 12 (1994) 1722-1733
74. Rodriguez-Bigas M.A., Chang G.J., and Skibber J.M. Surgical implications of colorectal cancer genetics. Surg Oncol Clin N Am 15 1 (2006) 51-66 vi
75. Al-Tassan N., et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 30 2 (2002) 227-232
76. Sampson J.R., et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 362 9377 (2003) 39-41
77. Guillem J.G., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24 28 (2006) 4642-4660
78. Bertagnolli M.M. Surgical prevention of cancer. J Clin Oncol 23 2 (2005) 324-332
79. Debinski H.S., et al. Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology 110 4 (1996) 1028-1030
80. Bertario L., et al. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol 10 3 (1994) 225-234
81. Church J., and Simmang C. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 46 8 (2003) 1001-1012
82. Vasen H.F., et al. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 348 9025 (1996) 433-435
83. Bertario L., et al. Genotype and phenotype factors as determinants for rectal stump cancer in patients with familial adenomatous polyposis. Hereditary Colorectal Tumors Registry. Ann Surg 231 4 (2000) 538-543
84. Remzi F.H., et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum of ten years. Dis Colon Rectum 46 1 (2003) 6-13
85. Parc Y.R., et al. Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg 233 3 (2001) 360-364
86. Setti-Carraro P., et al. The first 10 years' experience of restorative proctocolectomy for ulcerative colitis. Gut 35 8 (1994) 1070-1075
87. Delaney C.P., et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg 238 2 (2003) 221-228
88. Watson P., and Riley B. The tumor spectrum in the Lynch syndrome. Fam Cancer 4 3 (2005) 245-248
89. Fitzgibbons Jr. R.J., et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Ann Surg 206 3 (1987) 289-295
90. Rodriguez-Bigas M.A., et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann Surg 225 2 (1997) 202-207
91. Guillem J.G., et al. Gastrointestinal polyposis syndromes. Curr Probl Surg 36 4 (1999) 217-323
92. Lindor N.M., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296 12 (2006) 1507-1517
93. Jarvinen H.J., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 5 (2000) 829-834
94. Van Dalen R., et al. Patterns of surgery in patients belonging to Amsterdam-positive families. Dis Colon Rectum 46 5 (2003) 617-620
95. Lin K.M., et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 2 1 (1998) 67-71
96. de Vos tot Nederveen Cappel W.H., et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 52 12 (2003) 1752-1755
97. Vasen H.F., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110 4 (1996) 1020-1027
98. Lin K.M., et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 41 4 (1998) 428-433
99. Romeo G., et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367 6461 (1994) 377-378
100. Cohen M.S., et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 235 5 (2002) 648-654 [discussion: 654-5]
101. Gagel R.F., et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111 10 (1989) 802-806
102. Brandi M.L., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 12 (2001) 5658-5671
103. Simpson N.E., et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328 6130 (1987) 528-530
104. Donis-Keller H., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2 7 (1993) 851-856
105. Mulligan L.M., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 6428 (1993) 458-460
106. Wells Jr. S.A., et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220 3 (1994) 237-247 [discussion: 247-50]
107. Eng C., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 19 (1996) 1575-1579
108. Mulligan L.M., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6 1 (1994) 70-74
109. Eng C., and Mulligan L.M. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 9 2 (1997) 97-109
110. Vasen H.F., et al. Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration. A study of 15 kindreds in The Netherlands. Am J Med 83 5 (1987) 847-852
111. Skinner M.A., et al. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 31 1 (1996) 177-181 [discussion: 181-2]
112. Frilling A., et al. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 118 6 (1995) 1099-1103 [discussion: 1103-4]
113. Pacini F., et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 118 6 (1995) 1031-1035
114. Skinner M.A., et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353 11 (2005) 1105-1113
115. Guilford P., et al. E-cadherin germline mutations in familial gastric cancer. Nature 392 6674 (1998) 402-405
116. Gayther S.A., et al. Identification of germline E-cadherin mutations in gastric cancer families of European origin. Cancer Res 58 18 (1998) 4086-4089
117. Brooks-Wilson A.R., et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 41 7 (2004) 508-517
118. Kaurah P., et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297 21 (2007) 2360-2372
119. Lewis F.R., et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery 130 4 (2001) 612-617 [discussion: 617-9]
120. Chun Y.S., et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?. Cancer 92 1 (2001) 181-187
121. Huntsman D.G., et al. Early gastric cancer in young, asymptomatic carriers of germline E-cadherin mutations. N Engl J Med 344 25 (2001) 1904-1909
122. Charlton A., et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53 6 (2004) 814-820
123. Shaw D., et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?. Gut 54 4 (2005) 461-468